75730 Federal Register / Vol. 65, No. 233 / Monday, December 4, 2000 / Notices

TABLE 1.—SUBSTANCES RECOMMENDED FOR TESTING—Continued

Substance [CAS Number] Nominated by ICCEC recommendations Study rationale; other information

S-Adenosylmethionine,

[29908–03–0].

National Cancer Institute —In vitro genotoxicity testing (Syrian hamster embryo cell transformation and

DNA alkylation assays).

Widespread exogenous human exposure

through use as a dietary supplement;

limited toxicity data available.

—Subchronic toxicity testing dependent

on results of genotoxicity studies.

Senna ................................ Food and Drug ............... —Carcinogenicity testing in p53 ................ Data needed to complete safety

[8013–11–4] ....................... Administration ................. transgenic mouse model ............................ evaluation of stimulant laxatives;

transgenic studies will complement

manufacturer sponsored carcinogenicity

studies.

TABLE 2.—SUBSTANCES FOR WHICH A TESTING RECOMMENDATION IS DEFERRED PENDING RECEIPT AND CONSIDERATION

OF ADDITIONAL INFORMATION

Substance [CAS Number] Nominated by Nominated for Nomination rationale Additional information needed

1,3-Dichloropropane,

[142–28–9], 2,2-

Dichloropropane,

[594–20–7], 1,1-

Dichloropropene,

[563–58–6].

Environmental Protection Agency;

National Institute

of Environmental

Health Sciences.

—Short-term comprehensive drinking water toxicity

studies.

Drinking water contaminants with

high health research priority;

very limited toxicity data; known

toxicity and carcinogenicity of

structurally similar compounds.

Additional drinking water occurrence data; production volumes;

potential sources of drinking

water contamination; anticipated

regulatory value of additional

toxicity data.

—Pharmacokinetics

—Medaka studies ....

—Testing in human

bladder cell transformation model.

Hydergine, [8067–24–

1].

National Cancer Institute.—Genotoxicity testing.Ergot alkaloid prescription drug

with recent increase in ‘‘off

label’’ and dietary supplement

use in healthy individuals; lack

of available information on toxicity and carcinogenicity.

Dietary supplement sales and use

information; regulatory agency

information needs.

Yohimbe bark extract,

[85117–22–2], Yohimbine, [146–48–5].

National Cancer Institute.—Micronucleus

assay.

Significant human exposure

through use as a dietary supplement; suspicion of carcinogenicity of yohimbine based on

structural similarity to reserpine.

Dietary supplement use levels and

patterns; regulatory agency

informaiton needs.

[FR Doc. 00–30715 Filed 12–1–00; 8:45 am]

BILLING CODE 4140–00–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Substance Abuse and Mental Health

Services Administration

Agency Information Collection

Activities: Submission for OMB

Review; Comment Request

Periodically, the Substance Abuse and

Mental Health Services Administration

(SAMHSA) will publish a list of

information collection requests under

OMB review, in compliance with the

Paperwork Reduction Act (44 U.S.C.

Chapter 35). To request a copy of these

documents, call the SAMHSA Reports

Clearance Officer on (301) 443–7978.

Treatment Improvement Protocols

(TIPs) Evaluation Project—Prospective

Study—New—Since 1993, SAMHSA’s

Center for Substance Abuse Treatment

has published 37 Treatment

Improvement Protocols, which provide

administrative and clinical practice

guidance to the substance abuse

treatment field. This is the third of three

major studies and is designed to assess

readers’ use of TIPs and the impact of

TIPs on changing substance abuse

treatment practices.

The Prospective Study seeks to

determine the most cost effective level

of support needed by substance abuse

treatment providers to implement in

practice the information contained in

TIPs. Specifically, this study will

examine the use of TIP # 35,

‘‘Enhancing Motivation for Change in

Substance Abuse Treatment,’’ by

treatment professionals in four different

areas of the country. The study will use

a pretest/post-test experimental design

in which treatment facilities will be

randomly assigned to one of four

conditions: (1) The control group

(which will receive the TIP and no

additional support); (2) a TIP-plus

curriculum group; (3) a TIP-plus

curriculum and training group; and (4)

a TIP-plus curriculum, training, and

ongoing support group.

Data will be collected at baseline and

follow-up. Measures will include

providers’ awareness of TIP 35, their

knowledge of the content contained in

this TIP, their attitudes toward the TIP

and its content, and their use of this TIP

and its impact on practices within their

facilities. Burden for State substance

abuse (SSA) agency directors in the four

areas of the country chosen will consist

of information gathering by telephone.

Burden for other respondents will

consist of completing the pretest and

post-test questionnaires. The total

estimated burden for this project, to be

completed in a 1-year period, is

summarized below.

Federal Register / Vol. 65, No. 233 / Monday, December 4, 2000 / Notices 75731

Respondent Number of

respondents

Responses/

respondent

Average burden/response

(hrs.)

Total burden

(hrs.)

SSA Directors ................................................................................................ 6 1 1.0 6

Pretest:

Facility Directors ..................................................................................... 577 1 .14 81

Clinical Supervisors ................................................................................ 577 1 .14 81

Program Counselors ............................................................................... 2,350 1 .14 329

Post-test:

Facility Directors ..................................................................................... 577 1 .19 110

Clinical Supervisors ................................................................................ 577 1 .19 110

Program Counselors ............................................................................... 2,350 1 .19 447

Total ................................................................................................. 3,510 ........................ .......................... 1,164

Written comments and

recommendations concerning the

proposed information collection should

be sent within 30 days of this notice to:

Stuart Shapiro, Human Resources and

Housing Branch, Office of Management

and Budget, New Executive Office

Building, Room 10235, Washington, DC

20503.

Dated: November 27, 2000.

Richard Kopanda,

Executive Officer, SAMHSA.

[FR Doc. 00–30757 Filed 12–1–00; 8:45 am]

BILLING CODE 4162–20–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Substance Abuse and Mental Health

Services Administration

Center for Substance Abuse

Prevention; Notice of Meeting

Pursuant to Public Law 92–463,

notice is hereby given of the meeting of

the Center for Substance Abuse

Prevention (CSAP) Drug Testing

Advisory Board to be held in December

2000. A portion of the meeting will be

open and will include a Department of

Health and Human Services drug testing

program update, a Department of

Transportation drug testing program

update, and an update on the draft

guidelines for alternative specimen

testing and on-site testing.

If anyone needs special

accommodations for persons with

disabilities, please notify the Contact

listed below.

The meeting will also include the

review, discussion, and evaluation of

sensitive National Laboratory

Certification Program (NLCP) internal

operating procedures and program

development issues. Therefore, a

portion of the meeting will be closed to

the public as determined by the

SAMHSA Administrator in accordance

with Title 5 U.S.C. 552b(c)(2), (4), and

(6) and 5 U.S.C. App. 2, section 10(d).

A roster of the board members may be

obtained from: Mrs. Giselle Hersh,

Division of Workplace Programs, 5600

Fishers Lane, Rockwall II, Suite 815,

Rockville, MD 20857, Telephone: (301)

443–6014. The transcript for the open

session will be available on the

following website: www.health.org/

workplace. Additional information for

this meeting may be obtained by

contacting the individual listed below.

Committee Name: Center for Substance

Abuse Prevention Drug Testing Advisory

Board.

Meeting Date: December 5, 2000; 8:30

a.m.–4:30 p.m.; December 6, 2000; 8:30 a.m.–

3:30 p.m.

Place: Embassy Suites Hotel, 4300 Military

Road, Chevy Chase, Maryland 20815.

Type: Open: December 5, 2000; 8:30 a.m.–

Noon; Closed: December 5, 2000; Noon–4:30

p.m.; Closed: December 6, 2000; 8:30 a.m.–

3:30 p.m.

Contact: Donna M. Bush, Ph.D., Executive

Secretary, Telephone: (301) 443–6014, and

FAX: (301) 443–3031.

This notice is being published less than 15

days prior to the meeting due to the urgent

need to meet timing limitations imposed by

the review and funding cycle.

Dated: November 27, 2000.

Toian Vaughn,

Committee Management Officer, Substance

Abuse and Mental Health Services

Administration.

[FR Doc. 00–30699 Filed 12–1–00; 8:45 am]

BILLING CODE 4162–20–U

DEPARTMENT OF THE INTERIOR

Fish and Wildlife Service

Extension of Comment Period: Draft

Policy on Maintaining the Ecological

Integrity of the National Wildlife Refuge

System

AGENCY: Fish and Wildlife Service,

Interior.

ACTION: Notice, extension of comment

period.

SUMMARY: We are extending the

comment period on the Federal Register

notice dated October 17, 2000 (65 FR

61356) that invites the public to

comment on our draft ecological

integrity policy.

DATES: Submit comments on or before

December 15, 2000.

ADDRESSES: Send comments concerning

this draft ecological integrity policy via

mail, fax or email to: Elizabeth

Souheaver, Chief, Branch of Wildlife

Resources, National Wildlife Refuge

System, U.S. Fish and Wildlife Service,

4401 North Fairfax Drive, Room 670,

Arlington, Virginia 22203; fax (703—

358–2248; email: ecointegrity lpolicyl

comments @fws.gov.

FOR FURTHER INFORMATION CONTACT:

Elizabeth Souheaver, Chief, Branch of

Wildlife Resources, (703) 358–1744.

SUPPLEMENTARY INFORMATION: In a

Federal Register notice dated October

17, 2000, we published our draft

ecological integrity policy. We propose

to establish an internal policy to guide

personnel of the National Wildlife

Refuge System (System) in

implementing the clause of the National

Wildlife Refuge System Improvement

Act of 1997 that calls for maintaining

the ‘‘biological integrity, diversity, and

environmental health’’ of the System.

The holistic integration of these three

qualities constitutes ecological integrity.

We received several requests to

extend the public comment period

beyond the December 1, 2000 due date.

In order to ensure that the public has an

adequate opportunity to review and

comment on our draft policy, we are

extending the comment period to

December 15, 2000.

Dated: November 29, 2000.

Jamie Rappaport Clark,

Director, U.S. Fish and Wildlife Service.

[FR Doc. 00–30781 Filed 12–1–00; 8:45 am]

BILLING CODE 4310–55–P